Navigation Links
New Form of Painkiller May Fight Colon Cancer
Date:4/21/2010

Lab tests suggest that variation of naproxen might nip cancer in the bud, expert says,,

WEDNESDAY, April 21 (HealthDay News) -- Adding to previous research suggesting that painkillers can reduce the risk for colon cancer, researchers report that an investigational form of the drug naproxen blocks a molecular process that leads to the disease.

Commonly known by such brand names as Aleve, Anaprox and Naprosyn, the standard form of naproxen is a generic pain medication.

Though the drug has been tested only in the laboratory, not on people, "it appears that the investigational form of naproxen we studied may be more effective than standard naproxen in inhibiting colorectal tumor development," Margie Clapper, co-leader of the Cancer Prevention and Control Program at Fox Chase Cancer Center, said in a news release from the center. "An added benefit would be the reduced gastrointestinal toxicity of this novel type of naproxen."

Researchers found that the new type of naproxen, known as NO-naproxen, appeared to block a signaling pathway that plays a role in the formation of colorectal cancer.

Based on laboratory data, "we think that NO-naproxen is much better than naproxen in nipping this whole process in the bud," Clapper said.

The scientists are testing their finding in mice but do not yet have the results.

The study findings were scheduled to be released at the annual meeting of the American Association for Cancer Research, April 17 to 21 in Washington D.C.

More information

The American Cancer Society has more about colon cancer.



-- Randy Dotinga



SOURCE: Fox Chase Cancer Center, news release, April 21, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Page: 1

Related medicine news :

1. Another perk of painkillers? Decreased hormone levels may reduce cancer risk
2. Painkillers Lower Estrogen Levels, May Explain Cancer Reduction Risk
3. Overdoses From Prescription Painkillers on the Rise
4. Makers of Powerful Painkillers Present Safety Plans
5. San Francisco Firefighters: Increased Risk for Bladder Cancer – Testing Underway
6. Firefighters Walk Over 60,000 Miles in Blue Cross Blue Shield of Massachusetts' Fitness Challenge
7. Hormone Therapy May Fight Resistant Prostate Cancer
8. Registration Now Open for Little Red Door's Unite 2 Fight Race Against Prostate Cancer Saturday, July 10, 2010
9. Author Erin Morrow Still Releases "Fighting MS: Strength in Numbers"
10. Scientists Find Clues to How the Body Fights Off HIV
11. Sokolove Law Helps Thousands of Consumers Fight Unfair Disability Insurance Denial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... ... Grocery Company to the list of fine retailers selling biodegradable, hanging flushable wipes ... H.E.B., a large supermarket chain headquartered in San Antonio, Texas, operates more than ...
(Date:4/28/2017)... ... April 28, 2017 , ... Accreditation Commission for Health Care ... of America (HCAOA). This agreement allows HCAOA members to receive special pricing on ... on Accreditation University (AU) educational resources that help prepare HCAOA members for ACHC ...
(Date:4/28/2017)... ... April 28, 2017 , ... Getting enough sleep affects much more than energy – ... just 19 hours without sleep can compromise motor reaction time, which can increase the risk ... Insurance is sharing the following tips from the NSF to help you sleep better and ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back ... joined the revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified ... The patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike ...
(Date:4/28/2017)... MA (PRWEB) , ... April 28, 2017 , ... People ... for older people. “Wearing a hearing aid doesn’t have the stigma it had when ... & Hearing Associates of Greater Boston, in a NALA North American Speaker Series ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... 19, 2017  Novartis today announced the publication ... Lung, and Blood Institute (NHLBI) of the National ... patients with treatment-naïve severe aplastic anemia (SAA) achieved ... eltrombopag at the initiation of and concurrently with ... three sequential treatment groups, or cohorts. Cohort 3 ...
(Date:4/18/2017)... 18, 2017 Cogentix Medical, Inc. (NASDAQ: CGNT), ... Urology, Uro/Gyn and Gynecology markets with innovative and proprietary ... ended March 31, 2017 after the market close on ... will host a conference call and webcast to discuss ... 2, 2017 at 4:30 p.m. Eastern Time (3:30 p.m. ...
Breaking Medicine Technology: